These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 32588385)

  • 1. Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin: A Two-Year, Multicenter, Retrospective Study.
    Van Hise NW; Chundi V; Didwania V; Anderson M; McKinsey D; Roig I; Sharma A; Petrak RM
    Drugs Real World Outcomes; 2020 Jun; 7(Suppl 1):41-45. PubMed ID: 32588385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Use of Oritavancin for the Treatment of Osteomyelitis.
    Scoble PJ; Reilly J; Tillotson GS
    Drugs Real World Outcomes; 2020 Jun; 7(Suppl 1):46-54. PubMed ID: 32588387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of chronic osteomyelitis with multidose oritavancin: A case series and literature review.
    Chastain DB; Davis A
    Int J Antimicrob Agents; 2019 Apr; 53(4):429-434. PubMed ID: 30537532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oritavancin: A Long-Half-Life Lipoglycopeptide.
    Saravolatz LD; Stein GE
    Clin Infect Dis; 2015 Aug; 61(4):627-32. PubMed ID: 25900171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus.
    Corey GR; Arhin FF; Wikler MA; Sahm DF; Kreiswirth BN; Mediavilla JR; Good S; Fiset C; Jiang H; Moeck G; Kabler H; Green S; O'Riordan W;
    Int J Antimicrob Agents; 2016 Nov; 48(5):528-534. PubMed ID: 27665522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Outcomes and Economic Impact of Oritavancin for Gram-Positive Infections: A Single Academic Medical Center Health System Experience.
    Brownell LE; Adamsick ML; McCreary EK; Vanderloo JP; Ernst EJ; Jackson ER; Schulz LT
    Drugs Real World Outcomes; 2020 Jun; 7(Suppl 1):13-19. PubMed ID: 32592120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections.
    Stewart CL; Turner MS; Frens JJ; Snider CB; Smith JR
    Infect Dis Ther; 2017 Jun; 6(2):277-289. PubMed ID: 28386776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful Treatment of Methicillin Susceptible Staphylococcus aureus Osteomyelitis with Oritavancin.
    Delaportas DJ; Estrada SJ; Darmelio M
    Pharmacotherapy; 2017 Aug; 37(8):e90-e92. PubMed ID: 28543367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CHROME Study, a Real-world Experience of Single- and Multiple-Dose Oritavancin for Treatment of Gram-Positive Infections.
    Redell M; Sierra-Hoffman M; Assi M; Bochan M; Chansolme D; Gandhi A; Sheridan K; Soosaipillai I; Walsh T; Massey J
    Open Forum Infect Dis; 2019 Nov; 6(11):ofz479. PubMed ID: 31844635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.
    Corey GR; Good S; Jiang H; Moeck G; Wikler M; Green S; Manos P; Keech R; Singh R; Heller B; Bubnova N; O'Riordan W;
    Clin Infect Dis; 2015 Jan; 60(2):254-62. PubMed ID: 25294250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple-Dose Oritavancin Evaluation in a Retrospective Cohort of Patients with Complicated Infections.
    Schulz LT; Dworkin E; Dela-Pena J; Rose WE
    Pharmacotherapy; 2018 Jan; 38(1):152-159. PubMed ID: 29121395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Real-World Economic and Clinical Management of Adult Patients with Skin and Soft Tissue Infections (SSTIs) with Oritavancin: Data from Two Multicenter Observational Cohort Studies.
    Estrada S; Lodise TP; Tillotson GS; Delaportas D
    Drugs Real World Outcomes; 2020 Jun; 7(Suppl 1):6-12. PubMed ID: 32588389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-dose oritavancin in the treatment of acute bacterial skin infections.
    Corey GR; Kabler H; Mehra P; Gupta S; Overcash JS; Porwal A; Giordano P; Lucasti C; Perez A; Good S; Jiang H; Moeck G; O'Riordan W;
    N Engl J Med; 2014 Jun; 370(23):2180-90. PubMed ID: 24897083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oritavancin Versus Daptomycin for Osteomyelitis Treatment After Surgical Debridement.
    Van Hise NW; Petrak RM; Shah K; Diaz M; Chundi V; Redell M
    Infect Dis Ther; 2024 Mar; 13(3):535-547. PubMed ID: 38421519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial.
    Dunbar LM; Milata J; McClure T; Wasilewski MM;
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3476-84. PubMed ID: 21537018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections.
    Brade KD; Rybak JM; Rybak MJ
    Infect Dis Ther; 2016 Mar; 5(1):1-15. PubMed ID: 26831328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple Weekly Dalbavancin Dosing for the Treatment of Native Vertebral Osteomyelitis Caused by Methicillin-Resistant Staphylococcus Aureus: A Case Report.
    Almangour TA; Fletcher V; Alessa M; Alhifany AA; Tabb D
    Am J Case Rep; 2017 Dec; 18():1315-1319. PubMed ID: 29222405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Real-world Patient Registry for Oritavancin Demonstrates Efficacy and Safety Consistent With the Phase 3 SOLO Program.
    Redell M; Moeck G; Lucasti C; Durso S; Kennedy C; Fusaro K; Loutit J; Dudley M
    Open Forum Infect Dis; 2018 Jun; 5(6):ofy051. PubMed ID: 29977954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oritavancin as sequential therapy for Gram-positive bloodstream infections.
    Texidor WM; Miller MA; Molina KC; Krsak M; Calvert B; Hart C; Storer M; Fish DN
    BMC Infect Dis; 2024 Jan; 24(1):127. PubMed ID: 38267844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis and treatment of diabetic foot infections.
    Lipsky BA; Berendt AR; Deery HG; Embil JM; Joseph WS; Karchmer AW; LeFrock JL; Lew DP; Mader JT; Norden C; Tan JS;
    Plast Reconstr Surg; 2006 Jun; 117(7 Suppl):212S-238S. PubMed ID: 16799390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.